D. Huebner

发表

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia

K. Venkatakrishnan, D. Mould, Xiaofei Zhou, 2017, British journal of clinical pharmacology.

Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia

J. Gabrilove, H. Kantarjian, T. Kovacsovics, 2012, Leukemia & lymphoma.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

R. Collins, P. Hari, M. Maris, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.

S. Pileri, P. Zinzani, D. Huebner, 2016, Critical reviews in oncology/hematology.

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies

Manish R. Patel, K. Venkatakrishnan, J. Nemunaitis, 2017, Investigational New Drugs.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Nademanee, P. Stiff, V. Bachanova, 2015, The Lancet.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy

J. Walewski, A. Engert, N. Siritanaratkul, 2018, British journal of haematology.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

J. Connors, K. Savage, Y. Oki, 2017, The New England journal of medicine.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Scott E. Smith, J. Connors, K. Savage, 2016, Blood.

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

Scott E. Smith, N. Bartlett, O. O’Connor, 2015, Leukemia & lymphoma.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

R. Advani, S. Horwitz, T. Illidge, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Scott E. Smith, R. Advani, N. Bartlett, 2014, Journal of Hematology & Oncology.

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

J. Connors, S. Ansell, A. Younes, 2013, The Lancet. Oncology.

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.

S. Pileri, P. Zinzani, D. Huebner, 2016, Critical reviews in oncology/hematology.

Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

K. Nackaerts, T. Owonikoko, D. Spigel, 2016 .

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, New England Journal of Medicine.

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2014 .

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

F. Gao, A. DeMichele, B. Melichar, 2017, EBioMedicine.

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2013 .

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2013 .

Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

P. Stiff, V. Bachanova, T. Masszi, 2016, Clinical advances in hematology & oncology : H&O.

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

A. Nademanee, P. Stiff, V. Bachanova, 2015 .

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

P. Stiff, V. Bachanova, T. Masszi, 2014 .

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Scott E. Smith, J. Connors, K. Savage, 2013 .

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2016 .

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

M. Weichenthal, R. Dummer, O. Akilov, 2017, The Lancet.

Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

R. Collins, P. Hari, M. Maris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

M. Maris, G. Borthakur, C. Cogle, 2022, Blood.

Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Scott E. Smith, J. Connors, K. Savage, 2015, Clinical advances in hematology & oncology : H&O.

Plerixafor Can Predictably Mobilize Hematopoietic Stem Cells in Patients With Multiple Myeloma Previously Treated With Lenalidomide

P. Mcsweeney, D. Huebner, I. Micallef, 2009 .

Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis

A. Gautam, E. Wu, R. Ayyagari, 2015, Current medical research and opinion.

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

A. Stamatoullas, T. Illidge, A. Gautam, 2018, British journal of haematology.

836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

A. Tolcher, K. Papadopoulos, R. Mosher, 2020 .

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

K. Nackaerts, T. Owonikoko, D. Spigel, 2017 .

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

A. Tolcher, T. Burns, Melissa L. Johnson, 2020 .

Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat

A. Gautam, D. Huebner, Shih-Yuan Lee, 2018, Leukemia & lymphoma.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data

E. Wu, A. Macalalad, D. Huebner, 2015, Current medical research and opinion.

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

P. Stiff, T. Masszi, J. Walewski, 2014 .

984TiPPHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+ MATURE T-CELL LYMPHOMAS (MTCL).

L. Trümper, T. Illidge, B. Pro, 2014, Annals of Oncology.

Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are ≥ 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.

J. Gabrilove, H. Kantarjian, S. Eckert, 2009 .

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

K. Savage, Y. Oki, J. Radford, 2018, The New England journal of medicine.

Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines.

R. Fimmers, P. Albers, D. Schmidt, 2003, Anticancer research.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

A. DeMichele, B. Melichar, E. Dees, 2017, EBioMedicine.